血清中期因子水平对肝细胞癌患者TACE治疗反应的诊断和评估

肝脏 ›› 2023, Vol. 28 ›› Issue (9): 1072-1074.

血清中期因子水平对肝细胞癌患者TACE治疗反应的诊断和评估

王凯骊, 胡晓炜, 殷剑, 刘庆阳, 王秋波

214000 江苏苏州大学附属无锡九院检验科(王凯骊,殷剑,刘庆阳,王秋波);214000 无锡江南大学附属医院检验科(胡晓炜)

收稿日期:2022-10-13 出版日期:2023-09-30 发布日期:2023-10-24
通讯作者: 王秋波,Email:wangqiubo2020@suda.edu.cn
基金资助:
无锡市科技发展资金医疗卫生技术攻关项目(Y20212054)

Diagnosis and evaluation of serum midkine levels in response to TACE treatment in patients with hepatocellular carcinoma

WANG Kai-li¹, HU Xiao-wei², YIN Jian¹, LIU Qing-yang¹, WANG Qiu-bo¹

1. Department of Clinical Lab, Wuxi No.9 Institute Affiliated to Suzhou University, Jiangsu 214000,China;
2. Department of Clinical Lab, Affiliated Hospital of Jiangnan University, Wuxi 214000, China

Received:2022-10-13 Online:2023-09-30 Published:2023-10-24
Contact: WANG Qiu-bo,Email:wangqiubo2020@suda.edu.cn

摘要/Abstract

摘要： 目的分析血清中期因子(MK)水平对HCC患者TACE治疗反应的诊断和评估。方法前瞻性收集2020年1月—2022年5月在苏州大学附属无锡九院拟行TACE治疗的HCC患者40例和健康正常者30例,采用ELISA法测定血清MK浓度。根据RECIST标准将接受TACE治疗后的病例分为有效组和无效组,比较组间及治疗前后的血清MK水平。结果治疗有效、无效分别为18例、22例。肝癌组治疗前的血清MK为740.9 (456.2, 933.3) ng /L,显著高于正常组[164.5 (114.9, 200.3) ng /L, Z=6.415, P<0.001]。对肝癌组的疗效进行分析,有效组治疗前的血清MK为570.0 (280.0, 782.3) ng /L,治疗后的血清MK为147.5 (103.4, 213.5) ng /L;无效组治疗前的血清MK为899.9 (676.1, 1213.0) ng /L,治疗后的血清MK为469.0 (300.0, 837.5) ng /L。有效组和无效组在治疗前和治疗后的血清MK值差异均有统计学意义(治疗前:Z=2.990, P=0.003;治疗后:Z=4.758, P<0.001)。有效组在治疗前后血清MK降低的中位数为361.0 (136.3, 648.6) ng /L, 无效组在治疗前后血清MK降低的中位数为354.9 (238.9, 516.3) ng /L, 组间差异无统计学意义(Z=0.068, P>0.05)。结论血清MK水平对HCC患者TACE治疗反应的诊断和评估具有一定价值。

关键词: 肝细胞癌, 经导管动脉化疗栓塞, 中期因子

Abstract: Objective To analyze the level of serum medium-term factor (MK) in diagnosing and evaluating the response to TACE treatment in HCC patients.Methods 40 HCC patients scheduled to receive TACE treatment and 30 normal healthy subjects were prospectively collected from Wuxi No.9 Institute Affiliated to Suzhou University between January 2020 and May 2022, The serum MK concentration was determined by ELISA. The HCC patients treated with TACE were divided into effective group and ineffective group based on RECIST criteria. Serum MK levels were compared between groups and HCC patients before and after treatment. Results 18 cases were effective and 22 cases were ineffective. The serum MK level in the HCC group before treatment was 740.9 (456.2, 933.3) ng/L, which was significantly higher than that of the normal group [164.5 (114.9, 200.3) ng/L, Z=6.415, P<0.001]. The curative effect of liver cancer group was analyzed. In the effective group, the serum MK level before treatment was 570.0 (280.0, 782.3) ng/L, and the serum MK after treatment was 147.5 (103.4, 213.5) ng/L. In the ineffective group, the serum MK level before treatment was 899.9 (676.1, 1213.0) ng/L, and 469.0 (300.0, 837.5) ng/L after treatment. There were significant differences in serum MK levels between the effective group and the ineffective group before and after treatment (before treatment: Z=2.990, P=0.003; After treatment: Z=4.758, P<0.001). The median decrease of serum MK before and after treatment in the effective group was 361.0 (136.3, 648.6) ng/L, while it was 354.9 (238.9, 516.3) ng/L in the ineffective group. There was no significant difference between the two groups (Z=0.068, P>0.05). Conclusion The level of serum MK has diagnostic and evaluative value in assessing the response to TACE in HCC patients.

Key words: Hepatocellular carcinoma, Transcatheter arterial chemoembolization, Midkine

王凯骊, 胡晓炜, 殷剑, 刘庆阳, 王秋波. 血清中期因子水平对肝细胞癌患者TACE治疗反应的诊断和评估[J]. 肝脏, 2023, 28(9): 1072-1074.

WANG Kai-li, HU Xiao-wei, YIN Jian, LIU Qing-yang, WANG Qiu-bo. Diagnosis and evaluation of serum midkine levels in response to TACE treatment in patients with hepatocellular carcinoma[J]. Chinese Hepatolgy, 2023, 28(9): 1072-1074.

参考文献

[1] Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol,2017,34(2):153-159.
[2] Sim HW, Knox J. Hepatocellular carcinoma in the era of immunotherapy. Curr Probl Cancer,2018,42(1):40-48.
[3] Lee KH, Sung KB, Lee DY, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma: anatomic and hemodynamic considerations in the hepatic artery and portal vein. Radiographics,2002,22(5):1077-1091.
[4] Chang KT, Liu CJ, Tsai HT, et al. Effects and safety of body positioning on back pain after transcatheter arterial chemoembolization in people with hepatocellular carcinoma: A randomized controlled study. Int J Nurs Stud,2020,109:103641.
[5] Gunji T, Kawauchi N, Akahane M, et al. Long-term outcomes of transcatheter arterial chemoembolization with autologous blood clot for unresectable hepatocellular carcinoma. Int J Oncol.2002,21(2):427-432.
[6] 吴水天. CT增强扫描在评估原发性肝细胞肝癌TACE术后疗效中的应用. 中国CT和MRI杂志,2022,20(3):91-93.
[7] Sato Y, Watanabe H, Sone M, et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci,2013,118(1):16-22.
[8] Zhang ZZ, Wang G, Yin SH, et al. Midkine: A multifaceted driver of atherosclerosis. Clin Chim Acta,2021,521:251-257.
[9] Campbell VK, Gately RP, Krishnasamy R, et al. Midkine and chronic kidney disease-associated multisystem organ dysfunctions. Nephrol Dial Transplant,2021,36(9):1577-1584.
[10] Tsuchiya N, Sawada Y, Endo I, et al. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol,2015,21(37):10573-10583.
[11] Lu Q, Li J, Cao H, et al. Comparison of diagnostic accuracy of Midkine and AFP for detecting hepatocellular carcinoma: a systematic review and meta-analysis. Biosci Rep,2020,40(3): BSR20192424.
[12] Zhu WW, Guo JJ, Guo L, et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res,2013,19(14):3944-3954.
[13] 乔敏, 赵一鉴, 张建巧, 等. TACE联合射频消融治疗原发性肝癌患者疗效研究. 实用肝脏病杂志,2021,24(1):119-122.
[14] Zheng L, Li H, Huang J, et al. Serum midkine levels for the diagnosis and assessment of response to interventional therapy in patients with hepatocellular carcinoma. J Interv Med,2020,4(1):39-45.

[1]	葛舒, 刘洋洋. 超声造影与增强CT对肝内胆管癌与肝细胞癌的鉴别价值[J]. 肝脏, 2023, 28(9): 1075-1078.
[2]	张翔, 李莹莹, 汤青, 李伟, 孙立柱. CD8⁺ T淋巴细胞水平对晚期肝细胞癌患者免疫治疗疗效的评估价值[J]. 肝脏, 2023, 28(9): 1084-1087.
[3]	彭国庆, 王小梅, 王瑞, 余欢, 王思涵. 术前炎症标志物评估肝细胞癌手术预后价值的研究进展[J]. 肝脏, 2023, 28(9): 1123-1126.
[4]	聂彬, 赵铁军, 张胜龙. 肝细胞癌伴微血管侵犯不同切缘方案下根治术的预后分析[J]. 肝脏, 2023, 28(8): 921-923.
[5]	徐嘉嫔, 邵春燕, 刘地发, 许亚春. 体素内不相干运动扩散加权成像对肝细胞癌微血管侵犯预测和TACE疗效的评估价值[J]. 肝脏, 2023, 28(8): 938-942.
[6]	袁庆功, 张焱, 李军辉, 杨文彬. 纤连蛋白Ⅲ型结构域蛋白5对HepG2肝癌细胞体外转移活性的影响及其机制[J]. 肝脏, 2023, 28(8): 943-946.
[7]	王庆, 范芯铷, 汪慧. 重视晚期肝癌肝功能状态对免疫检查点抑制剂疗效的评估[J]. 肝脏, 2023, 28(7): 751-752.
[8]	黄倩, 李亚楠, 曾达武. ANLN、CYP2C9、HMMR在乙型肝炎病毒相关肝细胞癌中的表达及其对预后的影响[J]. 肝脏, 2023, 28(7): 775-780.
[9]	陈倩倩, 杨玥, 倪文婧, 芮法娟, 施军平, 李婕. 非酒精性脂肪性肝病相关肝细胞癌的防治策略研究进展[J]. 肝脏, 2023, 28(6): 639-643.
[10]	马伯恒, 王霞, 吴颖. 肉瘤样肝细胞癌血清生化指标、病理特征及手术疗效评估[J]. 肝脏, 2023, 28(6): 676-679.
[11]	靳志恩, 徐攀, 袁宏伟, 徐敬江. HCV感染者接受直接抗病毒药物治疗肝细胞癌风险变化[J]. 肝脏, 2023, 28(6): 680-682.
[12]	黄梦, 钱晓寒, 杨丽华. 环状RNA应用于肝细胞癌无创早期诊断的研究进展[J]. 肝脏, 2023, 28(6): 720-724.
[13]	肖滢, 吴治念, 王亚东. 肝素非抗凝作用在肝病应用中的研究进展[J]. 肝脏, 2023, 28(6): 730-733.
[14]	武超玉. 以发热为主要表现的肝脏原发性平滑肌肉瘤1例[J]. 肝脏, 2023, 28(6): 741-742.
[15]	黄孙桦, 刘建东, 黄罡. 肝细胞癌免疫治疗生物标志物的研究进展[J]. 肝脏, 2023, 28(5): 510-512.